Generic Name and Formulations:
Avatrombopag 20mg; tabs.
Indications for DOPTELET:
Thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.
Start treatment 10–13 days prior to a procedure. Should undergo procedure within 5–8 days after last dose. Take with food. Platelet count (<40 x 109/L): 60mg once daily for 5 days; (40–<50 x 109/L): 40mg once daily for 5 days.
Obtain platelet count prior to treatment and on day of procedure. Increased thrombotic risk with known risk factors (eg, Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, Protein C or S deficiency). Do not use to normalize platelet counts. Pregnancy; may cause fetal harm. Nursing mothers: not recommended (during and for ≥2 weeks after last dose).
Thrombopoietin receptor agonist.
Pyrexia, abdominal pain, nausea, headache, fatigue, peripheral edema; thrombotic/thromboembolic complications.
Neurology Advisor Articles
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- High Daily Stress Linked to Migraine Prevalence in Women
- Researchers Identify Coffee Component That May Provide Neuroprotection
- Functional Imaging in Movement Disorders: Diagnostic Advantages
- Dextroamphetamine Plus Physical Therapy Nonsuperior to Placebo for Improving Post-Stroke Motor Recovery
- Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy